Canine
Canine Hypothyroidism: Diagnosis and Treatment Monitoring
Bottom line
Diagnose canine hypothyroidism from a compatible phenotype and an interpretable thyroid panel, not an isolated low total T4. ALIVE recommends concurrent total T4 and canine TSH as first-line assessment in a dog with supportive findings. [1] Separate diagnostic uncertainty from treatment monitoring before committing a patient to long-term supplementation.
Establish why this dog needs thyroid testing
A low T4 with reference-interval TSH can occur in primary hypothyroidism, nonthyroidal illness, medication exposure or some healthy dogs. Thyroid autoantibody positivity supports thyroiditis but does not establish loss of thyroid function. [1]
Record the signs that prompted testing, their time course, previous laboratory findings and competing explanations. Distinguish an incidental laboratory result from a persistent clinical syndrome. Review recent and ongoing medications, previous supplementation and the patient's condition when the sample was collected.
In a diabetic dog with changing control, the long-term canine diabetes pathway places endocrine investigation within a broader review of delivery, diet, monitoring and comorbidity. Avoid treating a thyroid result as the explanation for every glucose fluctuation.
Interpret discordant results before prescribing
AAHA warns that breed, age, medications, stress and illness can reduce total T4; severe illness can also suppress free T4. Testing after clinical stabilization or recovery improves interpretability when feasible. [2]
Write down which uncertainty the next test should resolve. A dog with compatible signs and an inconclusive panel needs a different plan from a clinically well dog with an incidental low result. If testing must proceed during illness or medication exposure, retain those limitations in the interpretation rather than reporting a definitive endocrine label.
Cornell's diagnostic laboratory describes valid free T4 methods, the importance of separating free from protein-bound hormone, and antibody interference in thyroid testing. TSH should be combined with other thyroid tests. [3]
Ask the performing laboratory which assay was used, what interference is plausible and whether additional testing or a repeat sample would answer the question. Retain the original report and reference intervals. A laboratory consultation is particularly useful when the biochemical pattern conflicts with the clinical picture or prior results.
Keep neurological localization independent
AAHA describes facial paralysis, vestibular disease and polyneuropathy among less common reported associations. [2] Their presence does not establish a thyroid cause in an individual dog.
The canine facial-paralysis workup addresses ocular protection, peripheral versus central localization and otic or structural alternatives. Continue that assessment when the neurological findings require it; a low T4 should not close an unresolved localization problem.
Treat confirmed disease and make monitoring reproducible
AAHA recommends oral levothyroxine replacement and emphasizes the effect of food on absorption and interpretation of monitoring. It describes post-pill total T4 sampling 4–6 hours after administration and initial reassessment 4 weeks after starting or adjusting supplementation, unless clinical concerns require earlier assessment. [2]
Choose the product and regimen for the individual patient using applicable prescribing information and the treating clinician's plan. Record the actual formulation, administration relative to food, dose history and sample timing. Inconsistent delivery or an undocumented sampling interval makes a result harder to use safely.
Monitoring targets also require context. ALIVE describes an upper-half or slightly higher reference-interval total T4 target for once-daily therapy, while stating that the optimal target for twice-daily therapy is not well defined. [1] Do not erase that schedule distinction when applying a laboratory result.
At each review, reconcile clinical response, adverse effects and the actual administration process before changing therapy. Decide what remains unexplained rather than escalating supplementation solely because every original sign has not disappeared.
Observe subclinical patterns without manufacturing clinical disease
ALIVE does not recommend treatment of subclinical hypothyroidism and notes that increased TSH with reference-interval T4 has alternative explanations, including recovery from illness and medication-related changes. [1]
Give the referring clinician a clear conclusion: confirmed clinical disease, suspected disease needing further clarification, or an abnormality being monitored. Name the next assessment and the person responsible for reviewing it. If the original diagnosis is uncertain in a dog already receiving supplementation, arrange specialist or laboratory-supported reassessment rather than making unplanned withdrawal or dose changes.
Frequently Asked Questions
Does an isolated low total T4 establish canine hypothyroidism?
No. ALIVE recommends concurrent thyroid-output and feedback assessment in a dog with supportive clinical or clinicopathological findings. [1]
Can normal TSH exclude primary hypothyroidism?
No. Normal TSH can occur in primary hypothyroidism and must be interpreted with the rest of the panel and clinical context. [1]
Does a positive thyroglobulin antibody result prove thyroid hormone deficiency?
No. It supports thyroiditis, but does not by itself demonstrate thyroid hypofunction. [1]
Can severe nonthyroidal illness also lower free T4?
Yes. AAHA notes that severe illness can suppress free T4 as well as total T4, complicating interpretation. [2]
Why discuss the free T4 assay with the laboratory?
Methods differ; the laboratory should clarify assay selection and management of possible antibody interference. [3]
Should every asymptomatic dog with increased TSH receive levothyroxine?
No. The ALIVE subclinical definition requires context and exclusion of mimics, and it does not recommend routine treatment of subclinical hypothyroidism. [1]
Is there one established post-pill target for every dosing schedule?
No. ALIVE describes a once-daily target but states that the optimal target for twice-daily treatment is not well defined. [1]
References
- Niessen et al. Agreeing Language in Veterinary Endocrinology (ALIVE): Hypothyroidism, Hyperthyroidism, (Euglycaemic) Diabetic Ketosis/Ketoacidosis, and Diabetic Remission—A Modified Delphi-Method-Based System to Create Consensus Definitions. Veterinary Sciences. (2026)
- Bugbee et al. 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines. Journal of the American Animal Hospital Association. (2023)
- Cornell University Animal Health Diagnostic Center. Canine Thyroid Testing. Professional laboratory guidance. (n.d.)
Voyage Dispatch · thevoyage.ai/forvets/knowledge/canine-hypothyroidism-diagnosis-management · published Nov 15, 2026 · verify dosing against the current formulary before prescribing
More clinical updates
Canine Diabetes Mellitus: Long-Term Clinical Management
Interpret diabetic signs and glucose trends together, verify insulin delivery and investigate changing response before escalating treatment in dogs.
Read →Canine Facial Paralysis: Neurologic Localization and Diagnostic Workup
A localization-first approach to canine CN VII dysfunction, separating peripheral facial neuropathy, middle-ear disease, brainstem lesions, and mimics while protecting the cornea.
Read →Canine Primary Hyperparathyroidism: Diagnosis and Treatment
Confirm PTH-dependent canine hypercalcemia, select local treatment and plan postoperative calcium surveillance using procedure-specific evidence.
Read →Canine Diabetic Ketoacidosis: Inpatient Decisions
Separate ketone, glucose and clinical recovery endpoints when treating canine DKA, and interpret insulin-protocol evidence without overstating outcomes.
Read →